Combined Treatment of Sintilimab, Peg-aspargase Plus Anlotinib in NK/T Cell Lymphoma

Clinical trial NCT03936452 · COMPLETED

Trial details

NCT number: NCT03936452
Sponsor: Sun Yat-sen University
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type Early Stage Anlotinib Peg-aspargase Sintilimab Phase Two Open Radiotherapy

Start date: 2019-04-28
Primary completion: 2021-12-30
Enrollment: 55

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.